350 related articles for article (PubMed ID: 33418513)
21. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.
Raveendra-Panickar D; Finlay D; Layng FI; Lambert LJ; Celeridad M; Zhao M; Barbosa K; De Backer LJS; Kwong E; Gosalia P; Rodiles S; Holleran J; Ardecky R; Grotegut S; Olson S; Hutchinson JH; Pasquale EB; Vuori K; Deshpande AJ; Cosford NDP; Tautz L
J Biol Chem; 2022 Jan; 298(1):101477. PubMed ID: 34896393
[TBL] [Abstract][Full Text] [Related]
22. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types.
Vazhappilly CG; Saleh E; Ramadan W; Menon V; Al-Azawi AM; Tarazi H; Abdu-Allah H; El-Shorbagi AN; El-Awady R
Invest New Drugs; 2019 Apr; 37(2):252-261. PubMed ID: 29947013
[TBL] [Abstract][Full Text] [Related]
24. Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors.
Bagdanoff JT; Chen Z; Acker M; Chen YN; Chan H; Dore M; Firestone B; Fodor M; Fortanet J; Hentemann M; Kato M; Koenig R; LaBonte LR; Liu S; Mohseni M; Ntaganda R; Sarver P; Smith T; Sendzik M; Stams T; Spence S; Towler C; Wang H; Wang P; Williams SL; LaMarche MJ
J Med Chem; 2019 Feb; 62(4):1781-1792. PubMed ID: 30688462
[TBL] [Abstract][Full Text] [Related]
25. Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
Quintana E; Schulze CJ; Myers DR; Choy TJ; Mordec K; Wildes D; Shifrin NT; Belwafa A; Koltun ES; Gill AL; Singh M; Kelsey S; Goldsmith MA; Nichols R; Smith JAM
Cancer Res; 2020 Jul; 80(13):2889-2902. PubMed ID: 32350067
[TBL] [Abstract][Full Text] [Related]
26. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
[TBL] [Abstract][Full Text] [Related]
27. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics.
Jin WY; Ma Y; Li WY; Li HL; Wang RL
Comput Biol Chem; 2018 Apr; 73():179-188. PubMed ID: 29494926
[TBL] [Abstract][Full Text] [Related]
28. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
[TBL] [Abstract][Full Text] [Related]
29. Role of SHP2 in hematopoiesis and leukemogenesis.
Pandey R; Saxena M; Kapur R
Curr Opin Hematol; 2017 Jul; 24(4):307-313. PubMed ID: 28306669
[TBL] [Abstract][Full Text] [Related]
30. Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC.
Tang KH; Li S; Khodadadi-Jamayran A; Jen J; Han H; Guidry K; Chen T; Hao Y; Fedele C; Zebala JA; Maeda DY; Christensen JG; Olson P; Athanas A; Loomis CA; Tsirigos A; Wong KK; Neel BG
Cancer Discov; 2022 Jan; 12(1):47-61. PubMed ID: 34353854
[TBL] [Abstract][Full Text] [Related]
31. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.
Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL
Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294
[TBL] [Abstract][Full Text] [Related]
33. Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment.
Luo R; Fu W; Shao J; Ma L; Shuai S; Xu Y; Jiang Z; Ye Z; Zheng L; Zheng L; Yu J; Zhang Y; Yin L; Tu L; Lv X; Li J; Liang G; Chen L
Eur J Med Chem; 2023 May; 253():115305. PubMed ID: 37023678
[TBL] [Abstract][Full Text] [Related]
34. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation.
Liu WS; Jin WY; Zhou L; Lu XH; Li WY; Ma Y; Wang RL
J Comput Aided Mol Des; 2019 Aug; 33(8):759-774. PubMed ID: 31300938
[TBL] [Abstract][Full Text] [Related]
35. Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors.
Sahu P; Mitra A; Ganguly A
Int Rev Cell Mol Biol; 2024; 386():167-222. PubMed ID: 38782499
[TBL] [Abstract][Full Text] [Related]
36. Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2.
Chen C; Cao M; Zhu S; Wang C; Liang F; Yan L; Luo D
Sci Rep; 2015 Dec; 5():17626. PubMed ID: 26626996
[TBL] [Abstract][Full Text] [Related]
37. Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation.
Sha F; Kurosawa K; Glasser E; Ketavarapu G; Albazzaz S; Koide A; Koide S
J Mol Biol; 2023 Apr; 435(8):168010. PubMed ID: 36806475
[TBL] [Abstract][Full Text] [Related]
38. The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/MAPK pathway by brain-derived neurotrophic factor.
Easton JB; Royer AR; Middlemas DS
J Neurochem; 2006 May; 97(3):834-45. PubMed ID: 16573649
[TBL] [Abstract][Full Text] [Related]
39. Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.
Mitra R; Ayyannan SR
ChemMedChem; 2021 Mar; 16(5):777-787. PubMed ID: 33210828
[TBL] [Abstract][Full Text] [Related]
40. Allosteric modulation of SHP2: Quest from known to unknown.
Wang N; Zhu S; Lv D; Wang Y; Khawar MB; Sun H
Drug Dev Res; 2023 Nov; 84(7):1395-1410. PubMed ID: 37583266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
